Adwan L, Subaiea GM, Basha R, Zawia NH. Tolfenamic acid reduces tau
and CDK5 levels: Implications for dementia and tauopathies. Journal of
Neurochemistry. 2015 133(2):266-72. IF 4.244
Subaiea GM, Ahmed AH, Adwan LI, Zawia NH. Reduction of amyloid-beta deposition and attenuation of memory deficits by tolfenamic acid. Journal of Alzheimer's Disease. 2015 43(2):425-33. IF 3.612
3. Adwan L, Subaiea GM, Zawia NH. Tolfenamic acid downregulates BACE1
and protects against lead-induced upregulation of Alzheimer's disease related biomarkers. Neuropharmacology. 2014 79:596-62. IF 4.819
Subaiea GM, Adwan LI, Ahmed AH, Stevens KE, Zawia NH. Short-term
treatment with tolfenamic acid improves cognitive functions in Alzheimer's
disease mice. Neurobiology of Aging. 2013 34(10):2421-30. IF
Sankpal UT, Lee CM, Connelly SF, Kayaleh O, Eslin D, Sutphin R, Goodison S, Adwan
L, Zawia NH, Lichtenberger LM, Basha R. Cellular and
organismal toxicity of the anti-cancer small molecule, tolfenamic acid: a
pre-clinical evaluation. Cellular Physiology and Biochemistry. 2013 32(3):675-86. IF 3.55
LI, Zawia NH. Epigenetics: A novel therapeutic approach for the
treatment of Alzheimer’s disease. Pharmacology and Therapeutics.
2013 139(1):41-50. IF 8.562
LI, Basha R, Abdelrahim M, Subaiea GM, Zawia NH. Tolfenamic acid
interrupts the de novo synthesis of the beta-amyloid precursor protein and lowers
amyloid beta via a transcriptional pathway. Current Alzheimer Research.
2011 8(4):385-92. IF 3.953
R, Wu J, Adwan L, Maloney B, Basha MR, McPherson CA, Harry GJ, Rice DC,
Zawia NH, Lahiri DK. Lifespan profiles of Alzheimer's disease-associated
genes and products in monkeys and mice. Journal of Alzheimer's Disease.
2009 18(1):211-30. IF 3.612